Company intelligence / Profile preview

Faron Pharmaceuticals

Ownership: Public · FARN
Employees: ~55
Development stage: Phase 1

Overview

Faron’s lead asset bexmarilimab has shown positive topline results in the BEXMAB Phase II trial for high-risk MDS patients. The combination of bexmarilimab and azacitidine demonstrated a high overall response rate with good tolerability. FDA Fast Track Designation was granted for r/r MDS. Preparations are underway for a confirmatory Phase III trial as first-line therapy in HR MDS. Traumakine’s ARDS program was deprioritized after the HIBISCUS trial closed due to low COVID hospitalizations; it will now focus on organ protection indications.

Therapeutic areas: HematologyPulmonologyOncology
Modalities: Monoclonal antibodies (e.g., bexmarilimab, an anti-Clever‑1 antibody)Recombinant proteins/biologics (e.g., interferon beta‑1a in Traumakine)
Industry: Biotech

Drug pipeline

1 asset

bexmarilimab

Partnerships

Fred Hutchinson Cancer Research Center collaboration on CAR-T neurotoxicity projectAcademic collaborations supporting pipeline developmentParticipation in WHO Solidarity Trial & REMAP-CAP during COVID pandemic with Traumakine

Beyond the preview

Go deeper on Faron Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Faron Pharmaceuticals.

Explore the full profile